Breaking Finance News

Mateon Therapeutics Inc (NASDAQ:MATN) stock price target upped to $2.00, reported today by Roth Capital

Mateon Therapeutics Inc (NASDAQ:MATN) had its target raised to $2.00 by Roth Capital in a report released 4/20/2017. The new target price implies a potential upside of 1.47% from the company's previous closing price.

Previously on 03/13/2017, HC Wainwright reported on Mateon Therapeutics Inc (NASDAQ:MATN) increased the target price from $0.00 to $2.00. At the time, this indicated a possible upside of 2.23%.

Just yesterday Mateon Therapeutics Inc (NASDAQ:MATN) traded 10.06% higher at $0.81. Mateon Therapeutics Inc’s 50-day moving average is $0.69 and its 200-day moving average is $0.52. The last closing price is up 46.91% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 144,796 shares of MATN traded hands, up from an average trading volume of 82,461

Recent Performance Chart

Mateon Therapeutics Inc (NASDAQ:MATN)

Mateon Therapeutics Inc has 52 week low of $0.27 and a 52 week high of $1.02 and has a total market value of $0.

More About Mateon Therapeutics Inc (NASDAQ:MATN)

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.